Renal infiltration of colon adenocarcinoma is a rare event. The authors present the case report of a 52-year-old female who had a high carcinoembryonic antigen level 18 months after right hemicolectomy and a chemotherapy regimen to treat transverse colon adenocarcinoma. The patient presented cancer recurrence after 12 months, and underwent a paraaortic lymphadenoctomy and a second adjuvant chemotherapy with the folfox regimen. Abdomen computerized tomography revealed two solid masses in the right kidney, without evidence of any other metastatic sites. A nephrectomy was performed in the right kidney followed by adjuvant chemotherapy.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Protein abundance of drug transporters and drug-metabolizing enzymes in paired healthy and tumor tissue from colorectal cancer patients.
Int J Pharm
January 2025
Drug Delivery and Disposition, KU Leuven, Gasthuisberg ON2, Herestraat 49 - box 921, 3000 Leuven, Belgium. Electronic address:
The widespread prevalence of colorectal cancer and its high mortality rate emphasize the urgent need for more effective therapies. When developing new drug products, a key aspect is ensuring that sufficiently high concentrations of the active drug are reached at the site of action. Drug transporters and drug-metabolizing enzymes can significantly influence the absorption and local accumulation of drugs in intestinal tissue.
View Article and Find Full Text PDFCorrelation Between Grade of Clinical Response to Neoadjuvant Therapy for Rectal Cancer and Oncologic Outcomes in the Era of Watch-and-Wait.
Dis Colon Rectum
November 2024
Department of Colon and Rectal Surgery, Memorial Sloan Kettering Cancer Center, New York.
Background: The watch-and-wait strategy provides an opportunity to pursue non-operative management in rectal cancer patients with clinical complete response after neoadjuvant therapy. The management of those with near complete response remains controversial.
Objective: We assessed the oncologic outcomes of patients managed by watch-and-wait versus total mesorectal excision according to clinical response to neoadjuvant therapy.
Virulence factor discovery identifies associations between the Fic gene family and Fap2 fusobacteria in colorectal cancer microbiomes.
mBio
January 2025
Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
is a bacterium associated with colorectal cancer (CRC) tumorigenesis, progression, and metastasis. Fap2 is a fusobacteria-specific outer membrane galactose-binding lectin that mediates adherence to and invasion of CRC tumors. Advances in omics analyses provide an opportunity to profile and identify microbial genomic features that correlate with the cancer-associated bacterial virulence factor Fap2.
View Article and Find Full Text PDFTranscription factor FOXD1 and miRNA-204-5p play a major role in B4GALNT2 downregulation in colon cancer.
Sci Rep
January 2025
Department of Medical and Surgical Sciences (DIMEC), General Pathology Building, University of Bologna, Bologna, Italy.
The β1,4-N-acetylgalactosaminyltransferase 2 (B4GALNT2) which synthesizes the histo-blood group antigen Sd is highly expressed by normal colon, but it is dramatically down-regulated in colorectal cancer (CRC). High B4GALNT2 expression in CRC tissues is a marker of longer survival. The molecular bases of B4GALNT2 inhibition in CRC are largely obscure.
View Article and Find Full Text PDF[A new nortriterpenoid from mastic].
Zhongguo Zhong Yao Za Zhi
December 2024
Xinjiang Key Laboratory of Clean Conversion and High Value Utilization of Biomass Resources,School of Chemistry and Chemical Engineering, Yili Normal University Yining 835000, China School of Health, Jiangxi Normal University Nanchang 330022, China.
Ten compounds were separated by various modern chromatographic methods from mastic. They were identified by HR-ESI-MS, IR, UV, NMR, quantum chemical calculation of NMR(qcc-NMR) and comparison with reported data in literature as 17β-hydroxy-28-norolean-18-en-3-one(1), 28-norolean-12,17-dien-3,11-dione(2), 28-norolean-16,18-dien-3-one(3),(24Z)-26-hydroxy-7,24-dientirucalla-3-one(4), masticadienonic acid(5)、masticadienolic acid(6)、erythrodiol(7), 3β,28-dihydroxyoleana-11,13(18)-diene(8), 3-oxo-olean-9(11),12-dien-28-oic acid(9), and 12-oleane-3,11-dione(10). Among them, compound 1 was a novel compound and compound 2 was a novel natural product.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!